Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5194676
Max Phase: Preclinical
Molecular Formula: C56H70Cl4N8O12S2
Molecular Weight: 1253.17
Associated Items:
ID: ALA5194676
Max Phase: Preclinical
Molecular Formula: C56H70Cl4N8O12S2
Molecular Weight: 1253.17
Associated Items:
Canonical SMILES: CN1Cc2c(Cl)cc(Cl)cc2C(c2cccc(S(=O)(=O)NCCOCCOCCOCCNC(=O)Nc3ccc(NC(=O)NCCOCCOCCOCCNS(=O)(=O)c4cccc(C5CN(C)Cc6c(Cl)cc(Cl)cc65)c4)cc3)c2)C1
Standard InChI: InChI=1S/C56H70Cl4N8O12S2/c1-67-35-49(47-31-41(57)33-53(59)51(47)37-67)39-5-3-7-45(29-39)81(71,72)63-15-19-77-23-27-79-25-21-75-17-13-61-55(69)65-43-9-11-44(12-10-43)66-56(70)62-14-18-76-22-26-80-28-24-78-20-16-64-82(73,74)46-8-4-6-40(30-46)50-36-68(2)38-52-48(50)32-42(58)34-54(52)60/h3-12,29-34,49-50,63-64H,13-28,35-38H2,1-2H3,(H2,61,65,69)(H2,62,66,70)
Standard InChI Key: SGLYPVFGKAWJET-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1253.17 | Molecular Weight (Monoisotopic): 1250.3309 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Jacobs JW, Leadbetter MR, Bell N, Koo-McCoy S, Carreras CW, He L, Kohler J, Kozuka K, Labonté ED, Navre M, Spencer AG, Charmot D.. (2022) Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na+/H+ Exchanger Isoform 3., 13 (7.0): [PMID:35859876] [10.1021/acsmedchemlett.2c00037] |
Source(1):